Kiniksa Pharmaceuticals International Plc (KNSA) Stock Price, Financials & Summary

Price chart

Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23

Key dataOct 23, 2026

Open$80.16

From 52W high−7.74%

Volume571075.00

Market cap$5.99B

P/E (TTM)71.7x

P/S (TTM)7.1x

Div yield—

Key dataOct 23, 2026

Open

$80.16

From 52W high

−7.74%

Volume

571075.00

Market cap

$5.99B

ValuationView details →

P/E (Fwd)

43.8x

EV/EBITDA

48.8x

P/E (TTM)

71.7x

RSI (14)

47.4

MomentumView details →

1D Return

−5.03%

YTD Return

+87.45%

SummaryUpdated Jun 1, 2026

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biopharmaceutical company founded in 2015 and based in Hamilton, Bermuda. The company went public in May 2018 and focuses on developing and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Kiniksa has successfully transitioned from a development-stage company to a profitable commercial enterprise, primarily driven by the success of its flagship product ARCALYST for treating recurrent pericarditis, a rare inflammatory cardiovascular condition.

Ask drillr about Kiniksa Pharmaceuticals International Plc →

ValuationView details →

P/E (Fwd)

43.8x

P/E (TTM)

71.7x

EV/EBITDA

48.8x

EV/Sales

6.5x

P/S (TTM)

7.1x

P/B (TTM)

9.2x

ProfitabilityView details →

Gross Margin

54.49%

Net Margin

9.59%

EBITDA Margin

13.33%

ROE (TTM)

12.33%

ROA (TTM)

9.00%

Asset Turnover

0.98x

GrowthView details →

Revenue YoY

+58.85%

EPS YoY

+1683.33%

FCF YoY

+175.38%

Revenue CAGR 3Y

+45.45%

EPS CAGR 3Y

−32.83%

EBITDA YoY

+742.35%

MomentumView details →

1D Return

−5.03%

YTD Return

+87.45%

1Y Return

+98.63%

RSI (14)

47.4

vs 50D SMA

−1.02%

vs 200D SMA

+31.08%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.90x

Quick Ratio

3.49x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.30

EPS Surprise

0.17%

Beats (12Q)

8/12

Next Q EPS Est

$0.36

Avg Surprise (4Q)

−5.38%

Rev Surprise

7.56%

Financials snapshotView financials →

Revenue (TTM)

840.85M

Net Income (TTM)

80.66M

Op. CF (TTM)

185.23M

Next earningsOct 27, 2026 →

Latest newsMore news →

Kiniksa Pharmaceuticals International, plc reported Q2 2026 earnings of $0.3 per share, matching the Zacks Consensus Estimate and up from $0.23 per share a year ago.89d ago

Similar companies

悦康药业688658.SH Belite Bio, IncBLTE 科前生物688526.SH Ligand Pharmaceuticals IncorporatedLGND Immunovant, Inc.IMVT Terns Pharmaceuticals, Inc.TERN Find similar companies →

Latest newsMore news →

Kiniksa Pharmaceuticals International, plc reported Q2 2026 earnings of $0.3 per share, matching the Zacks Consensus Estimate and up from $0.23 per share a year ago.89d ago